ATRS Altiris Inc.

The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Antares Pharma, Inc.

NEW YORK--(BUSINESS WIRE)--

The Klein Law Firm announces the commencement of an investigation of Antares Pharma, Inc. (NASDAQ: ATRS) concerning possible violations of federal securities laws.

On October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration stating that the agency had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for its product candidate Xyosted.

Then on October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding the New Drug Application for Xyosted. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted “could cause a clinically meaningful increase in blood pressure” and also noted the FDA’s concerns “regarding the occurrence of depression and suicidality.”

If you suffered a loss in Antares and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/ATRS-Info-Request-Form-216.

Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
31/10/2017

Underlying

ATRSAltiris Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altiris Inc.

 PRESS RELEASE
Free
ATRS ALTIRIS INC.

Glancy Prongay & Murray Reminds Investors of the December 22, 2017 Dea...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the December 22, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Antares Pharma, Inc. (“Antares” or the “Company”) (NASDAQ: ATRS) securities between December 21, 2016, and October 12, 2017, inclusive (the “Class Period”). Antares investors have until December 22, 2017 to file a lead plaintiff motion. To obtain information or participate in the class action, please visit the Antare...

December 19, 2017 1 EN
 PRESS RELEASE
Free
ATRS ALTIRIS INC.

Scott+Scott, Attorneys at Law, LLP Reminds Investors of December 22nd ...

NEW YORK--(BUSINESS WIRE)-- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or the “Company”) and other defendants, related to alleged violations of federal securities laws. If you purchased Antares securities between December 21, 2016 and October 12, 2017, you are encouraged to a contact a Scott+Scott attorney at (844) 818-6982 for additional informat...

December 5, 2017 1 EN
 PRESS RELEASE
Free
ATRS ALTIRIS INC.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Antares Pharma, Inc. (Nasdaq: ATRS) (“Antares” or the “Company”) securities during the period between December 21, 2016 and October 12, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until December 22, 2017 to s...

November 30, 2017 1 EN
 PRESS RELEASE
Free
ATRS ALTIRIS INC.

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Antares Pharma, Inc. (NASDAQ:ATRS) who purchased shares between December 21, 2016 and October 12, 2017. The action, which was filed in the United States District Court for the District of New Jersey, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or ...

November 17, 2017 1 EN
 PRESS RELEASE
Free
ATRS ALTIRIS INC.

ATRS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investor...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Antares Pharma, Inc. ("Antares") (NASDAQ:ATRS) securities between December 21, 2016 and October 12, 2017. Click here to learn about the case: http://www.wongesq.com/pslra-sb/antares-pharma-inc?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period, the C...

November 7, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch